Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Advertisement
Set Alert for Articles By Mike Ward

Latest From Mike Ward

The Future's Bright For Microbiome Investing, Says VC

Seventure Partners’ Eric de la Fortelle explains how the venture capitalist’s €160bn fund will prosper from the increased understanding of human and microbe interactions.

Innovation Financing

vitalityDNA Plans To Keep Healthy People Healthy

vitalityDNA is taking the preventative approach to health care with its personalized health and lifestyle plan offering. The start-up will initially target consumers and then health care companies.

In Vitro Diagnostics StartUps and SMEs

Mitochondrial Medicine Focus Drives NeuroVive Orphan Ambitions

Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to Scrip about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.

Rare Diseases StartUps and SMEs

Infant Bacterial Therapeutics Harnesses Microbiome To Treat Preterm Babies

By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an approach to treat necrotizing enterocolitis, a major killer of premature babies.

StartUps and SMEs Business Strategies

Sinergium's Gateway To Latin American Vaccine & Biologics Markets

With the Latin American vaccines market forecast to more than quadruple in size from just over $150m to 2015 to just under $700m in 2020, opportunities abound for both homegrown businesses and multinationals looking to tap into local markets.

South America Vaccines

Chinese Capital Accesses Western Innovation To Create Homegrown Industry

With the Chinese market growing at 10-15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains how Chinese capital is accessing Western innovation to build a PRC pharma industry.

China Innovation
See All
Advertisement
UsernamePublicRestriction

Register